Incannex appoints Dr. Luigi Barbato as CMO; base salary $375K, RSU grant of 100,476 shares vesting over 3 years

Incannex Healthcare Inc.

Dr. Barbato appointed Chief Medical Officer effective October 21, 2024; reports to CEO Joel Latham.
Base salary of $375,000 with target annual incentive up to 20% of base salary.
Granted 100,476 restricted stock units (approx. $200K / 5-day VWAP) vesting in 3 equal annual installments.
Most recently Global Medical Lead at Jazz Pharmaceuticals; prior roles at AbbVie, Biogen, Novartis.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Luigi M. Barbato, M.D.

Chief Medical Officer

IXHL · Incannex Healthcare Inc.

Effective: 2024-10-21
Filed: October 24, 2024, 7:59 PM ET

Effective October 21, 2024 (the “Effective Date”), Incannex Healthcare Inc. (the “Company”) entered into an employment agreement (the “Employment Agreement”) with Luigi M. Barbato, M.D., to serve as the Company’s Chief Medical Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Luigi M. Barbato, M.D. was appointed as Chief Medical Officer at Incannex Healthcare Inc..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

Effective October 21, 2024 (the “Effective Date”), Incannex Healthcare Inc. (the “Company”) entered into an employment agreement (the “Employment Agreement”) with Luigi M. Barbato, M.D., to serve as the Company’s Chief Medical Officer.

View on SEC.gov

Incannex Healthcare Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-090121

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.